{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:41:41Z","timestamp":1790775701202,"version":"4.1.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>The optimal second-line therapy following first-line atezolizumab plus bevacizumab remains unascertained. In this study, we compared second-line durvalumab plus tremelimumab with lenvatinib after first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (uHCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective, open-label, non-randomized comparative study, we analyzed real-world data derived from a prospectively registered observational cohort of patients with uHCC who received durvalumab plus tremelimumab (the Dur\/Tre group, n\u2009=\u200914) or lenvatinib (the Len group, n\u2009=\u200967) as second-line therapy after first-line atezolizumab plus bevacizumab. Tumor response was assessed using the RECIST criteria version 1.1. Progression-free survival (PFS), overall survival (OS), adverse events (AEs), and changes in the albumin\u2013bilirubin (ALBI) score were compared between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The objective response and disease control rates were 7.7% and 15.4% in the Dur\/Tre group and 23.3% and 76.7% in the Len group, respectively. The median PFS was 1.7 vs. 4.2 months (p\u2009&lt;\u20090.001) and median OS was 5.3 vs. 14.0 months (p\u2009=\u20090.047) in the Dur\/Tre and Len groups, both significantly favoring lenvatinib. Multivariable analysis showed that lenvatinib treatment was an independent predictor of longer PFS, and a neutrophil-to-lymphocyte ratio\u2009\u2265\u20093 was an independent predictor of worse OS. Grade\u2009\u2265\u20093 AEs were more frequent with lenvatinib than with durvalumab plus tremelimumab (70.1% vs. 21.4%; p\u2009=\u20090.002). At week 4, the ALBI score was maintained with durvalumab plus tremelimumab (\u22122.30 to \u22122.21; p\u2009=\u20090.318) but worsened with lenvatinib (\u22122.36 to \u22121.97; p\u2009&lt;\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After first-line atezolizumab plus bevacizumab, second-line lenvatinib achieved superior disease control and longer survival than durvalumab plus tremelimumab. However, grade\u2009\u2265\u20093 AEs were more frequent with lenvatinib than with durvalumab plus tremelimumab. Careful AE management is therefore important when selecting therapy for individual patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0341395","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:36:52Z","timestamp":1778175412000},"page":"e0341395","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma"],"prefix":"10.1371","volume":"21","author":[{"given":"Chinatsu","family":"Nishioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9116-7054","authenticated-orcid":true,"given":"Yuki","family":"Tahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Maesaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8634-2922","authenticated-orcid":true,"given":"Kazuhiro","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Nakabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaharu","family":"Iio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruyasu","family":"Kakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-607X","authenticated-orcid":true,"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0777-8045","authenticated-orcid":true,"given":"Atsushi","family":"Hosui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2488-7315","authenticated-orcid":true,"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"4","key":"pone.0341395.ref001","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0341395.ref002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"A-L Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10126","key":"pone.0341395.ref003","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"pone.0341395.ref004","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"RS Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0341395.ref005","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"GK Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"15","key":"pone.0341395.ref006","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update","volume":"42","author":"JD Gordan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0341395.ref007","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"AG Singal","year":"2023","journal-title":"Hepatology"},{"issue":"10492","key":"pone.0341395.ref008","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"T Yau","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"pone.0341395.ref009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000514312","article-title":"Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy","volume":"10","author":"M Kudo","year":"2021","journal-title":"Liver Cancer"},{"issue":"10","key":"pone.0341395.ref010","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1111\/jgh.70068","article-title":"Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma","volume":"40","author":"K Maesaka","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"pone.0341395.ref011","article-title":"Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study","volume":"19","author":"M Kai","year":"2024","journal-title":"PLoS One"},{"issue":"2","key":"pone.0341395.ref012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000512781","article-title":"Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study","volume":"10","author":"C Yoo","year":"2021","journal-title":"Liver Cancer"},{"issue":"1","key":"pone.0341395.ref013","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00535-025-02308-x","article-title":"Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma","volume":"61","author":"K Maesaka","year":"2026","journal-title":"J Gastroenterol"},{"issue":"2","key":"pone.0341395.ref014","first-page":"127","article-title":"Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries","volume":"14","author":"C-K Lee","year":"2024","journal-title":"Liver Cancer"},{"issue":"10","key":"pone.0341395.ref015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1159\/000531316","article-title":"Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function","volume":"101","author":"A Hiraoka","year":"2023","journal-title":"Oncology"},{"issue":"22","key":"pone.0341395.ref016","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.3390\/cancers15225406","article-title":"Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma","volume":"15","author":"S Yano","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"pone.0341395.ref017","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/hepr.14160","article-title":"Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma","volume":"55","author":"T Yonemoto","year":"2025","journal-title":"Hepatol Res"},{"issue":"34","key":"pone.0341395.ref018","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039289","article-title":"Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma","volume":"103","author":"R Miura","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"pone.0341395.ref019","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/jjco\/hyaf017","article-title":"Systemic therapy for hepatocellular carcinoma, from the early to the advanced stage: a Japanese perspective","volume":"55","author":"M Ikeda","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"pone.0341395.ref020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"T Yamashita","year":"2020","journal-title":"J Gastroenterol"},{"issue":"9","key":"pone.0341395.ref021","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/hepr.13537","article-title":"Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension","volume":"50","author":"K Maesaka","year":"2020","journal-title":"Hepatol Res"},{"issue":"2","key":"pone.0341395.ref022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"pone.0341395.ref023","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"B Sangro","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"pone.0341395.ref024","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40801-024-00458-7","article-title":"Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment","volume":"11","author":"Y Fujiwara","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"8","key":"pone.0341395.ref025","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.3390\/curroncol31080315","article-title":"Early Changes in Alpha-Fetoprotein and Des-\u03b3-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma","volume":"31","author":"T Kuzuya","year":"2024","journal-title":"Curr Oncol"},{"issue":"2","key":"pone.0341395.ref026","doi-asserted-by":"crossref","first-page":"101232","DOI":"10.1016\/j.jhepr.2024.101232","article-title":"Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab\/bevacizumab","volume":"7","author":"M Wu","year":"2024","journal-title":"JHEP Rep"},{"issue":"3","key":"pone.0341395.ref027","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3350\/cmh.2023.0553","article-title":"Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab\/bevacizumab failure: A real-world study","volume":"30","author":"YE Chon","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"19","key":"pone.0341395.ref028","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients","volume":"3","author":"A Osa","year":"2018","journal-title":"JCI Insight"},{"issue":"10","key":"pone.0341395.ref029","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/cancers12103048","article-title":"Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1\/PD-L1 Checkpoint Blockade","volume":"12","author":"T Aoki","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"pone.0341395.ref030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10637-024-01470-y","article-title":"Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma","volume":"42","author":"N Mori","year":"2024","journal-title":"Invest New Drugs"},{"key":"pone.0341395.ref031","doi-asserted-by":"crossref","first-page":"216038","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Z Wang","year":"2023","journal-title":"Cancer Lett"},{"issue":"3","key":"pone.0341395.ref032","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/hepr.14136","article-title":"Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice","volume":"55","author":"A Hiraoka","year":"2025","journal-title":"Hepatol Res"},{"issue":"4","key":"pone.0341395.ref033","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/ol.2022.13489","article-title":"Immunosuppressive effects of vascular endothelial growth factor","volume":"24","author":"D Ribatti","year":"2022","journal-title":"Oncol Lett"},{"issue":"9","key":"pone.0341395.ref034","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.21873\/anticanres.17219","article-title":"Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma","volume":"44","author":"N Tamaki","year":"2024","journal-title":"Anticancer Res"},{"issue":"10","key":"pone.0341395.ref035","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3390\/cancers12102906","article-title":"Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment","volume":"12","author":"T Hatanaka","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"pone.0341395.ref036","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000502095","article-title":"Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma","volume":"97","author":"A Hiraoka","year":"2019","journal-title":"Oncology"},{"issue":"7","key":"pone.0341395.ref037","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/hepr.13771","article-title":"Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma","volume":"52","author":"K Maesaka","year":"2022","journal-title":"Hepatol Res"},{"issue":"21","key":"pone.0341395.ref038","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.3390\/cancers13215536","article-title":"Management of VEGFR-Targeted TKI for Thyroid Cancer","volume":"13","author":"T Enokida","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0341395.ref039","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"BI Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"pone.0341395.ref040","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/CMAR.S417238","article-title":"The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors","volume":"15","author":"S Takahashi","year":"2023","journal-title":"Cancer Manag Res"},{"issue":"2","key":"pone.0341395.ref041","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"MA Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0341395.ref042","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"F Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:36:58Z","timestamp":1778175418000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341395"}},"subtitle":[],"editor":[{"given":"Keun-Yeong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341395","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}